Signal Genetics Inc Share Price Nasdaq
Equities
US8266401046
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
09/05 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
09/05 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
Sales 2024 * | 235K 19.59M | Sales 2025 * | 330K 27.55M | Capitalization | 887M 74.07B |
---|---|---|---|---|---|
Net income 2024 * | -226M -18.87B | Net income 2025 * | -266M -22.21B | EV / Sales 2024 * | 1,811 x |
Net cash position 2024 * | 462M 38.6B | Net cash position 2025 * | 625M 52.2B | EV / Sales 2025 * | 794 x |
P/E ratio 2024 * |
-3.8
x | P/E ratio 2025 * |
-3.54
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.69% |
Latest transcript on Signal Genetics Inc
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30/23/30 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 01/23/01 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 03/18/03 |
Tomas Kiselak
CHM | Chairman | 38 | 28/20/28 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30/23/30 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |